Arbutus Biopharma

US · ABUS #3365 by market cap Listed 2015

4.29 -0.19 -4.24%

Live - 5344 symbols - heartbeat 28s ago · 2026-10-08 08:32

Pre-market 4.35 +1.31%

After-hours 4.30 +0.23%

Market cap: 849.87M
P/E (TTM): 5.43
P/B: 3.28
EPS: -0.17
Div yield: 0.00%
52W pos: 41%

Reader sentiment Are you bullish or bearish on ABUS?

Anonymous reader poll. Unscientific, not investment advice.

About Arbutus Biopharma

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Founded: 2005
CEO: Ms. Lindsay Androski, C.F.A.,J.D.,M.B.A.
Employees: 19
Headquarters: Warminster, Pennsylvania, United States of America
Fiscal year end: 12-31
Website: arbutusbio.com

Company profile

Exchange: US
Symbol: ABUS
Market-cap rank: #3365
Listing date: 2015-05-04
Market cap: 849.87M
Float cap: 526.05M
Shares out: 198.11M
Float shares: 122.62M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 08:32:55 · For reference only, not investment advice and not tailored to your situation.